Brief: Cantargia Reports Positive Preclinical Efficacy Data For CAN10

Cantargia AB

01/03/2022 10:06

March 1 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA REPORTS POSITIVE PRECLINICAL EFFICACY DATA FOR
CAN10
DEMONSTRATING ANTI-FIBROTIC AND ANTI-INFLAMMATORY EFFECTS IN
SYSTEMIC SCLEROSIS
    * ANNOUNCED NEW PRECLINICAL DATA ON ITS ANTI-INFLAMMATORY
IL1RAP-BINDING ANTIBODY CAN10 SHOWING THAT CAN10 REDUCED
ESTABLISHED FIBROSIS IN SKIN AND LUNGS IN AN ADVANCED MODEL OF
SYSTEMIC SCLEROSIS
    * CAN10 ALSO NORMALIZED BIOLOGICAL MARKERS OF INFLAMMATION
AND
FIBROSIS, ASSOCIATED WITH HUMAN DISEASE

Source text for Eikon:  ID:nWkr8377pL 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))